The International Journal of Biochemistry & Cell Biology
Molecules in focusMacrophage inflammatory protein-1
Introduction
Two recent and important findings have led to a renewed interest in MIP-1 proteins (MIP-1α, β, γ, δ), highly related ligands and activators of CC chemokine receptors (mainly CCR1, 3, and 5): (1) the MΦ effector chemokines CCL3 and CCL4, which are produced and secreted by activated MΦ to attract other proinflammatory cells, are also crucial in recruiting MΦ themselves to sites of inflammation; and (2) CCL3 can potently inhibit the MΦ uptake of HIV-1 via CCR5 ligation.
Section snippets
Structure
MIP-1 proteins are small (8–10 kDa), structurally related, inducible, secreted, and proinflammatory chemokines of the CC subfamily, one of four chemokine groups (i.e. CXC, C, CC, and CX3C) as defined by their primary structure. In mice and humans the MIP-1 family members CCL3 (mice: MIP-1α, human: MIP-1α/LD78α) and CCL4 (mice and human: MIP-1β) are encoded by genes consisting of three exons and two introns located on chromosomes 11 and 17, respectively (Fig. 1, Table 1). The highly related
Synthesis and degradation
The genes for CCL3 and CCL4 are inducible in most mature hematopoietic cells. Cells that are directly involved in eliciting immune responses, i.e. MΦ, T- and B-lymphocytes, neutrophils, dendritic cells, mast cells and NK cells, can produce large amounts of MIP-1 (up to several nanograms/106 cells). Platelets, osteoblasts, astrocytes and microglia, epithelial cells, fibroblasts and other cells produce less CCL3/4 upon stimulation. Generally, the synthesis (and release) of CCL3/4 requires cell
Biological function
MIP-1 proteins mediate their biological effects by binding to cell surface CC chemokine receptors (3×104 to 5×105 receptors per cell), which belong to the G-protein-coupled receptor superfamily (Table 1). Receptor binding involves high affinity interactions and a subsequent cascade of intracellular events that rapidly leads to a wide range of target cell functions including chemotaxis, degranulation, phagocytosis, and mediator synthesis. Signal transduction events are initiated by the G-protein
Possible medical applications
During the past years rapid advances have been made in the identification and characterization of MIP-1 receptor antagonists (Horuk, 2003). Potent, orally bioavailable, synthetic small molecule antagonists of both CCR1 and CCR5 are currently tested in phase I/II clinical trials (Carter, 2002). Their development is driven by two goals: (1) to inhibit the proinflammatory effects of MIP-1 proteins and other ligands of CCR1 and CCR5 that have been shown to contribute to the pathogenesis of
References (16)
Chemokine receptor antagonism as an approach to anti-inflammatory therapy: Just right or plain wrong?
Current Opinion in Chemical Biology
(2002)- et al.
Natural truncation of the chemokine MIP-1 beta/CCL4 affects receptor specificity but not anti-HIV-1 activity
Journal of Biological Chemistry
(2002) Development and evaluation of pharmaceutical agents targeting chemokine receptors
Methods
(2003)- et al.
Truncation of the NH2-terminal amino acid residues increases agonistic potency of leukotactin-1 on CC chemokine receptors 1 and 3
Journal of Biological Chemistry
(2002) - et al.
Macrophage inflammatory protein-1
Cytokine Growth Factor Reviews
(2002) - et al.
Chemokine receptors and their role in inflammation and infectious diseases
Blood
(2000) - et al.
Cleavage by CD26/dipeptidyl peptidase IV converts the chemokine LD78beta into a most efficient monocyte attractant and CCR1 agonist
Blood
(2000) - et al.
Strategies for chemokine antagonists as therapeutics
Seminars on Immunology
(2003)